CHRS Stock Recent News

Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). Coherus management has insisted they will "not engage in heavily discounted pricing" for the drug.

Coherus announced it has resubmitted a biologic license application for one of its products. The FDA had previously issued a complete response letter holding up the product's approval, citing an ongoing review at a manufacturing site.

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a treatment designed to cut cancer patients' risk of infection after chemotherapy. The rejection was due to ongoing review of inspection findings at a third-party filler and did not identify any issues with Udenyca Onbody's clinical efficacy, safety or device design, the company said.

It is about to be deleted from a popular small-cap equity index. As of Monday, Sept.

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

The immuno-oncology biotech specialist delivered stronger-than-expected revenue and earnings in Q2. Coherus also reiterated its full-year guidance and anticipates closing on its pending merger with Surface Oncology in Q3.

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Marek Ciszewski – Senior Vice President-Investor Relations Denny Lanfear – President, CEO and Chairman Paul Reider – Chief Commercial Officer Theresa LaVallee – Chief Development Officer Rosh Dias – Chief Medical Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Robyn Karnauskas – Truist Securities Michael Nedelcovych – TD Cowen Douglas Tsao – H.C. Wainwright Chris Schott – JPMorgan Ash Verma – UBS Operator Good day and thank you for standing by.

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.

Why would anyone want to buy penny stocks? They're extremely risky.